With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

KNOWING where to invest your cash is difficult as there are thousands of companies to choose from. That’s why Holly Mead, a ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of ...

The global Musculoskeletal Oncology Therapeutics Market is projected to grow from USD 2.2 billion in 2025 to USD 3.3 billion ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

The number of significant shareholder protests has more than doubled so far this year compared with a year ago, with 11 FTSE ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

In addition to Barclays, Sanofi also received a Buy from J.P. Morgan’s Richard Vosser in a report issued on August 8. However, on August 5, Deutsche Bank maintained a Hold rating on Sanofi (Other OTC: ...